Generate Biomedicines (NASDAQ:GENB) Posts Earnings Results, Misses Estimates By $0.04 EPS

Posted by Brian Himes on Aug 7th, 2026

Generate Biomedicines (NASDAQ:GENB – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04), FiscalAI reports. The business had revenue of $6.31 million for the quarter.

Generate Biomedicines Trading Up 1.5%

GENB stock traded up $0.21 on Friday, hitting $14.11. 232,194 shares of the company’s stock were exchanged, compared to its average volume of 667,250. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $18.18. The firm has a market capitalization of $1.81 billion and a PE ratio of -13.19. The stock’s 50 day simple moving average is $14.42.

Hedge Funds Weigh In On Generate Biomedicines

An institutional investor recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp bought a new stake in Generate Biomedicines Inc (NASDAQ:GENB – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 57,326 shares of the company’s stock, valued at approximately $967,000.

Wall Street Analyst Weigh In

GENB has been the subject of a number of research analyst reports. HC Wainwright raised their price objective on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Morgan Stanley raised their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Check Out Our Latest Report on Generate Biomedicines

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.